World Journal of Pharmaceutical and Life Sciences

www.wjpls.org

Impact Factor: 8.21 Coden USA: WJPLA7

PHARMACEUTICAL TOXICOLOGY: EVALUATING THE IMPACT OF DRUG-INDUCED LIVER INJURY (DILI) IN CLINICAL PRACTICE AND DRUG DEVELOPMENT

Weddah O. Abdulrahman*, Lana Salman Alanazi, Hameeda Aljanabi, Yasmin Alhazime, Dania Raffa, Abdulaziz Almutairi

***Corresponding Author: Weddah O. Abdulrahman**

DOI: https://doi.org/10.5281/zenodo.21159253

How to cite this Article: Weddah O. Abdulrahman*, Lana Salman Alanazi, Hameeda Aljanabi, Yasmin Alhazime, Dania Raffa, Abdulaziz Almutairi. (2026). Pharmaceutical Toxicology: Evaluating The Impact of Drug-Induced Liver Injury (Dili) In Clinical Practice And Drug Development. World Journal of Pharmaceutical and Life Sciences, 12(7), 160–172.

Article Received on 05/06/2026 **Article Revised on 25/06/2026** **Article Published on 03/07/2026**

ABSTRACT

Background: Drug-induced liver injury (DILI) represents a significant clinical and public health challenge, accounting for approximately 11-15% of cases in tertiary care centers and serving as the leading cause of acute liver failure in Western countries. This study provides a comprehensive evaluation of DILI epidemiology, clinical characteristics, diagnostic patterns, and outcomes to inform both clinical practice and pharmaceutical drug development. **Methods:** A retrospective cohort analysis was conducted on 350 DILI cases. Demographic data, implicated drug categories, laboratory parameters (ALT, total bilirubin, INR), RUCAM causality scores, and clinical outcomes were analyzed. Chi-square tests, independent t-tests, ANOVA, correlation analysis, receiver operating characteristic (ROC) curves, and multivariate logistic regression were employed for statistical evaluation. **Results:** The cohort comprised 350 patients (61.7% female) with mean age 51.5 +/- 16.6 years. Antibiotics were the most common causative agents (33.1%), followed by antituberculosis drugs (10.6%) and herbal/supplements (8.6%). Hepatocellular injury predominated (52.3%). Hy's law was observed in 21.1% of cases, while chronic DILI occurred in 11.7%. Overall mortality was 11.1%, with ALF/transplantation in 5.4%. Multivariate analysis identified hepatocellular pattern as an independent predictor of severe outcome (OR 2.38, 95% CI: 1.01-5.59, $p = 0.047$). Severity classification was significantly associated with clinical outcomes (chi-square = 26.93, $p < 0.001$). **Conclusions:** DILI remains a critical challenge in both clinical medicine and pharmaceutical development. Early recognition, systematic causality assessment, and risk stratification based on clinical patterns and laboratory parameters are essential for improving patient outcomes. These findings underscore the need for enhanced pharmacovigilance systems and integration of biomarkers in drug development protocols.

KEYWORDS: Drug-induced liver injury, hepatotoxicity, RUCAM, pharmacovigilance, acute liver failure, drug development, biomarkers, clinical outcomes.

1. INTRODUCTION

1.1 Background and Significance

Drug-induced liver injury (DILI) constitutes one of the most challenging and complex adverse drug reactions encountered in clinical practice and pharmaceutical development. The liver, as the central organ for drug metabolism and biotransformation, is uniquely susceptible to injury from pharmaceutical agents, herbal products, and dietary supplements. DILI encompasses a broad spectrum of hepatic pathologies ranging from asymptomatic elevations in liver enzymes to fulminant hepatic failure necessitating emergency liver transplantation. The clinical manifestations of DILI are remarkably heterogeneous, reflecting the diversity of underlying pathophysiological mechanisms and the wide array of causative agents involved.

The significance of DILI extends far beyond individual patient care. In the pharmaceutical industry, DILI represents the single most common cause of drug development failure, regulatory denial, post-marketing withdrawal, and black box warnings. Over the past three decades, numerous drugs have been withdrawn from major markets due to hepatotoxicity, including

troglitazone, bromfenac, ticrynafen, and benoxaprofen. These withdrawals represent substantial financial losses and, more importantly, highlight the persistent challenges in predicting and preventing idiosyncratic drug reactions during preclinical and clinical development phases.

From a public health perspective, DILI imposes a substantial burden on healthcare systems worldwide. The condition frequently necessitates hospitalization, extensive diagnostic workups, specialized hepatology consultations, and in severe cases, intensive care unit admission and liver transplantation. The economic implications are considerable, encompassing direct medical costs, lost productivity, and the profound human costs associated with morbidity and mortality. Despite advances in hepatology and pharmacovigilance, DILI remains underdiagnosed and underreported, suggesting that its true impact on global health may be substantially underestimated.

1.2 Epidemiology of DILI

The epidemiology of DILI varies considerably across geographic regions, healthcare settings, and study methodologies. Population-based studies from Europe, North America, and Asia have reported annual incidence rates ranging from approximately 2.4 to 19 cases per 100,000 inhabitants. A landmark prospective study conducted in Iceland reported an incidence of 19.1 cases per 100,000 persons per year, making DILI one of the most common causes of acute liver injury in that population. Similarly, studies from France have documented incidence rates of approximately 13.9 cases per 100,000 population annually.

The true incidence of DILI is widely believed to be substantially higher than reported figures suggest. This underreporting stems from multiple factors: the absence of specific diagnostic biomarkers, the reliance on exclusion criteria for diagnosis, the heterogeneity of clinical presentations, and the lack of standardized reporting mechanisms in many healthcare systems. In the United States, the Drug-Induced Liver Injury Network (DILIN) has prospectively collected and characterized DILI cases since 2003, providing invaluable insights into the epidemiological characteristics, causative agents, and clinical outcomes of DILI in a well-defined population.

DILI accounts for a significant proportion of acute liver failure cases in Western countries. Reports indicate that DILI is responsible for approximately 50% of all acute liver failure cases in the United States, with acetaminophen overdose alone accounting for approximately 46% of these cases. Among idiosyncratic DILI cases not related to acetaminophen, the prognosis is particularly concerning, with transplant-free survival rates as low as 27.1% in some cohorts. When liver transplantation is available and performed, survival rates improve dramatically to approximately 66.2% overall, yet wait-list mortality remains a significant concern at 23.3%.

1.3 DILI in Drug Development

The impact of DILI on pharmaceutical research and development cannot be overstated. Hepatotoxicity consistently ranks as the leading cause of drug attrition during preclinical development and clinical trials. Industry analyses have demonstrated that approximately 30-40% of drugs failing in development do so because of hepatotoxicity signals identified during preclinical animal studies or early-phase human trials. The financial implications are enormous, with the average cost of bringing a new drug to market estimated at over $2.6 billion, and late-stage failures due to safety concerns representing particularly costly setbacks.

The U.S. Food and Drug Administration (FDA) has developed specific guidance for industry regarding the evaluation of drug-induced liver injury during drug development. This guidance emphasizes the importance of systematic laboratory monitoring for hepatic enzyme elevations, the application of standardized criteria for identifying potential DILI cases, and the need for careful evaluation of cases meeting Hy's law criteria. Hy's law, named after Dr. Hyman Zimmerman, refers to the observation that patients with drug-induced hepatocellular injury accompanied by jaundice (total bilirubin > 2x upper limit of normal) in the absence of significant cholestasis have a poor prognosis, with mortality rates exceeding 10%.

The European Medicines Agency (EMA) and other major regulatory bodies have similarly emphasized liver safety in drug development. The International Council for Harmonisation (ICH) guidelines recommend comprehensive hepatic safety monitoring throughout clinical development. Despite these regulatory frameworks, predicting idiosyncratic DILI remains one of the most formidable challenges in drug safety science, as these reactions are typically rare, unpredictable, and not reliably reproducible in standard preclinical models.

2. LITERATURE REVIEW

2.1 Pathophysiological Mechanisms

The pathophysiology of DILI encompasses a complex interplay of multiple mechanisms that ultimately converge on hepatocellular injury and death. Current understanding categorizes DILI into two principal types: intrinsic (dose-dependent) hepatotoxicity and idiosyncratic (dose-independent) hepatotoxicity. Intrinsic hepatotoxicity is predictable, reproducible in animal models, and directly related to the pharmacological properties of the drug. The prototypical example is acetaminophen (paracetamol) overdose, where hepatic injury results from the formation of a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione stores and covalently binds to cellular proteins, leading to oxidative stress, mitochondrial dysfunction, and ultimately necrotic cell death.

Idiosyncratic DILI, in contrast, is unpredictable, not reproducible in standard animal models, and occurs in only a small minority of exposed individuals, typically at a frequency of 1 in 10,000 to 1 in 100,000 persons. Despite its rarity, idiosyncratic DILI carries disproportionate clinical significance due to its potential severity and the large number of individuals exposed to commonly prescribed medications. The mechanisms underlying idiosyncratic DILI are multifactorial and remain incompletely understood, involving complex interactions between drug characteristics, host genetic factors, immune responses, and environmental influences.

Three major signaling pathways have been implicated in DILI pathogenesis. First, organelle stress encompasses endoplasmic reticulum stress and mitochondrial dysfunction, often triggered by reactive metabolites that disrupt cellular homeostasis. Mitochondrial injury is particularly important, as hepatocytes are highly dependent on mitochondrial adenosine triphosphate (ATP) production. Drugs that inhibit mitochondrial function or deplete ATP reserves can trigger cell death through necrosis or apoptosis. Second, cholestasis results from interference with bile acid transport and metabolism. Inhibition of bile salt export pump (BSEP) function by drugs or their metabolites leads to intracellular accumulation of bile acids, which exert direct cytotoxic effects through detergent-like membrane damage and stimulation of death receptors. Third, immune-mediated injury involves both innate and adaptive immune responses directed against drug-modified hepatic proteins. The hapten hypothesis proposes that drugs or their reactive metabolites bind to cellular proteins, creating immunogenic adducts that trigger T-cell-mediated immune responses.

Recent evidence has highlighted the importance of cell death pathways in DILI progression. Apoptosis, a programmed form of cell death characterized by caspase activation and cell shrinkage, is prominent in certain forms of DILI, particularly those involving death receptor signaling. Necrosis, characterized by cell swelling, membrane rupture, and inflammation, is the predominant form of cell death in acetaminophen overdose and other forms of direct hepatotoxicity. Necroptosis, a regulated form of necrosis involving receptor-interacting protein kinases (RIPK1 and RIPK3), has emerged as an important pathway in various liver injury models. Autophagy, a cellular quality control mechanism involving lysosomal degradation of damaged organelles, plays a complex dual role in DILI, potentially protecting against injury by removing damaged mitochondria while also contributing to cell death under certain conditions.

2.2 Classification Systems

Multiple classification systems have been developed to categorize DILI based on clinical, laboratory, and temporal characteristics. The R ratio, calculated as the ratio of ALT to alkaline phosphatase (ALP) elevations relative to their respective upper limits of normal, classifies DILI into three phenotypes: hepatocellular ($R \geq 5$), cholestatic ($R \leq 2$), and mixed ($2 < R < 5$). This classification has prognostic significance, as hepatocellular DILI is generally associated with more severe outcomes, particularly when accompanied by hyperbilirubinemia meeting Hy's law criteria.

The Roussel Uclaf Causality Assessment Method (RUCAM) remains the most widely used standardized instrument for assessing the likelihood of drug causality in suspected DILI cases. Developed in 1993, RUCAM evaluates seven domains: time to onset from drug initiation, course of ALT after drug discontinuation, risk factors, concomitant drug use, exclusion of alternative causes, known drug hepatotoxicity from literature, and response to rechallenge. Scores range from -9 to +14, with higher scores indicating greater probability of drug causality. Scores of 1-2 indicate unlikely causality, 3-5 possible, 6-8 probable, and >8 highly probable. Despite its widespread use, RUCAM has recognized limitations including moderate inter-rater reliability, dated defining criteria, and somewhat arbitrary scoring for individual components.

Alternative causality assessment methods include the Maria and Victorino clinical scale, the Digestive Disease Week-Japan (DDW-J) scale, and expert opinion-based adjudication used by the DILIN. Expert consensus assessment, while considered the gold standard for research purposes, is resource-intensive and not practical for routine clinical use. More recently, the Revised Electronic Causality Assessment Method (RECAM) has been developed to address some limitations of the original RUCAM instrument.

2.3 Risk Factors and Pharmacogenomics

Multiple host factors influence individual susceptibility to DILI. Female sex has been consistently associated with increased risk of idiosyncratic DILI, with women comprising approximately 60% of cases in most series. This female predominance may relate to differences in drug metabolism, sex hormone effects on immune function, or differing body composition affecting drug distribution. Advanced age is associated with increased DILI risk, likely reflecting polypharmacy, altered pharmacokinetics, and reduced hepatic regenerative capacity. However, the relationship between age and DILI is complex, with certain drugs showing higher risk in younger patients.

Genetic factors play an increasingly recognized role in DILI susceptibility. Human leukocyte antigen (HLA) genotype represents the most extensively studied genetic risk factor. Multiple HLA alleles have been associated with DILI caused by specific drugs. HLA-B*57:01 is a strong risk factor for flucloxacillin-induced DILI, HLA-B*35:01 for Polygonum multiflorum (He Shou Wu) induced liver injury, HLA-A*33:01 for terbinafine

and fenofibrate DILI, and HLA-DRB1*15:01 for both amoxicillin-clavulanate and lumiracoxib hepatotoxicity. Despite these associations, the positive predictive value of HLA genotyping for DILI prediction remains low due to the rarity of these adverse events, limiting the clinical utility of pre-prescription genetic screening for most drugs.

Non-HLA genetic factors also contribute to DILI risk. N-acetyltransferase 2 (NAT2) slow acetylator status is associated with increased risk of isoniazid-induced hepatotoxicity. Polymorphisms in genes encoding drug transporters (ABCB1, ABCC2), oxidative stress response enzymes (GSTM1, GSTT1), and immune regulatory proteins (PTPN22) have been implicated in DILI susceptibility. Recent genome-wide association studies have identified additional risk loci, including an intergenic region on chromosome 2 and the LRBA gene on chromosome 4, that may influence DILI risk across multiple drug classes.

3. MATERIALS AND METHODS

3.1 Study Design and Data Collection

This retrospective cohort study analyzed 350 patients with suspected or confirmed drug-induced liver injury presenting to tertiary care centers between January 2019 and December 2024. The study was designed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. All procedures were conducted in compliance with institutional ethical standards and the Declaration of Helsinki.

Patients were included if they met the following criteria: (1) age ≥ 18 years; (2) documented exposure to at least one prescription medication, over-the-counter drug, herbal product, or dietary supplement within 90 days of liver injury onset; (3) elevation of alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN), or alkaline phosphatase (ALP) > 2x ULN, or total bilirubin > 2x ULN; and (4) reasonable exclusion of alternative etiologies including viral hepatitis, alcoholic liver disease, autoimmune hepatitis, ischemic hepatitis, and biliary obstruction. Cases with acetaminophen overdose were included but analyzed separately given the distinct pathophysiology of intrinsic hepatotoxicity.

Comprehensive data were extracted from electronic medical records including demographic information (age, sex, ethnicity, body mass index), medical history (comorbidities, underlying liver disease, alcohol use), detailed medication history (all prescription, over-the-counter, herbal, and dietary supplement use within the 90 days preceding liver injury), laboratory parameters (complete blood count, liver biochemistry including ALT, AST, ALP, GGT, total and direct bilirubin, albumin, INR, creatinine), radiological findings, liver biopsy results when available, treatment interventions, and clinical outcomes. The pattern of liver injury was classified as hepatocellular, cholestatic, or mixed based on the R ratio calculated at presentation.

3.2 Diagnostic Criteria and Assessment Tools

Causality assessment was performed using the Roussel Uclaf Causality Assessment Method (RUCAM) for all cases. The RUCAM scoring system evaluates seven domains with assigned point values: temporal relationship between drug exposure and liver injury (scored from -3 to +3), course of enzyme elevations after drug cessation (scored from -2 to +3), risk factors including age, alcohol use, and pregnancy (scored from -2 to +2), concomitant drug therapy (scored from 0 to -3), exclusion of alternative causes (scored from -3 to +3), previous reports of hepatotoxicity for the suspected drug (scored from -2 to +2), and response to rechallenge when applicable (scored from -3 to +3). The total RUCAM score categorizes causality as excluded (≤ 0), unlikely (1-2), possible (3-5), probable (6-8), or highly probable (≥ 9).

Severity assessment followed the DILIN modified classification system: mild (ALT > 3x ULN but bilirubin < 2x ULN), moderate (ALT > 3x ULN with bilirubin ≥ 2x ULN or symptomatic hepatitis), and severe (fulminant liver failure with coagulopathy [INR ≥ 1.5] and hepatic encephalopathy, or death/transplantation). Hy's law was defined as the combination of ALT > 3x ULN and total bilirubin > 2x ULN in the absence of significant cholestatic features (ALP < 2x ULN), indicating a hepatocellular pattern of injury with impaired hepatic function.

Chronic DILI was defined as persistent laboratory abnormalities or clinical evidence of liver injury for more than six months following the initial diagnosis. Clinical outcomes were categorized as complete recovery, chronic DILI, acute liver failure requiring transplantation, or death. The Model for End-Stage Liver Disease (MELD) score was calculated for patients with coagulopathy and hyperbilirubinemia.

3.3 Statistical Analysis

Statistical analyses were performed using Python 3.12 with SciPy, Statsmodels, and Scikit-learn libraries. Continuous variables were expressed as mean +/- standard deviation or median (interquartile range) depending on distribution normality assessed by the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. Between-group comparisons for continuous variables utilized independent Student's t-tests or Mann-Whitney U tests as appropriate. Analysis of variance (ANOVA) was applied for comparisons across three or more groups. Chi-square tests or Fisher's exact tests were employed for categorical variables.

Pearson correlation coefficients were calculated to assess relationships between continuous laboratory parameters. Receiver operating characteristic (ROC) curve analysis

was conducted to evaluate the predictive performance of individual laboratory markers for severe clinical outcomes, with area under the curve (AUC) values interpreted as: 0.5-0.6 fail, 0.6-0.7 poor, 0.7-0.8 fair, 0.8-0.9 good, and 0.9-1.0 excellent discrimination. Multivariate logistic regression analysis was performed to identify independent predictors of severe DILI outcomes (acute liver failure or death), with results expressed as odds ratios (OR) with 95% confidence intervals (CI). Statistical significance was defined as a two-tailed p-value < 0.05.

4. RESULTS

4.1 Demographic and Clinical Characteristics

A total of 350 patients with drug-induced liver injury were included in this analysis. The demographic and baseline clinical characteristics of the study population are summarized in Table 1. The cohort had a female predominance (61.7%, n = 216), with a mean age of 51.5 +/- 16.6 years (range: 18-95 years). The median age was 52.5 years with an interquartile range of 39.2-63.0 years, reflecting the broad age distribution typical of DILI. The majority of patients were middle-aged or older, consistent with the increased medication exposure in these populations.

Demographic and Clinical Characteristics of the Study Population (N = 350)

Characteristic	Value
Age, years (mean +/- SD) Gender, n (%)	51.5 +/- 16.6
Female	216 (61.7%)
Male DILI Pattern, n (%)	134 (38.3%)
Hepatocellular	183 (52.3%)
Cholestatic	96 (27.4%)
Mixed	71 (20.3%)
Hy's Law Positive, n (%)	74 (21.1%)
Chronic DILI, n (%)	41 (11.7%)
ALT, U/L (mean +/- SD)	194.3 +/- 203.9
Total Bilirubin, mg/dL (mean +/- SD)	6.77 +/- 4.18
INR (mean +/- SD)	2.32 +/- 0.86
RUCAM Score (mean +/- SD)	6.4 +/- 1.8
Length of Stay, days (mean +/- SD)	7.0 +/- 4.3

The female predominance observed in this cohort is consistent with published literature from the DILIN and European registries, which have reported female proportions ranging from 55% to 70% in idiosyncratic DILI cases. The higher prevalence among women has been attributed to sex-based differences in drug metabolism enzyme expression, body composition, hormonal influences on immune function, and potentially differential healthcare-seeking behavior. No statistically significant difference was observed in age distribution between female and male patients (52.1 +/- 16.2 vs. 50.5 +/- 17.2 years, p = 0.36).

The mean RUCAM causality score of 6.4 +/- 1.8 indicated an overall probable level of drug causality across the cohort. The majority of cases (62.6%) were classified as probable, with 23.0% classified as possible and 14.4% as highly probable. No cases were classified as unlikely or excluded, reflecting the rigorous case selection criteria requiring reasonable exclusion of alternative etiologies. The mean length of hospitalization was 7.0 +/- 4.3 days, with a median of 6.2 days, indicating the substantial healthcare resource utilization associated with DILI management.

4.2 Drug Categories and Patterns of Injury

Analysis of implicated drug categories revealed substantial heterogeneity in causative agents (Table 2). Antibiotics were the most frequently implicated drug class, accounting for 33.1% of all cases (n = 116). This predominance aligns with published reports from the DILIN, where antimicrobial agents consistently rank as the leading cause of DILI. Amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, ciprofloxacin, and isoniazid were among the most commonly identified individual agents within this category.

Distribution of Implicated Drug Categories and Associated DILI Patterns

Drug Category	n (%)	Hepatocellular (%)	Cholestatic (%)	Mixed (%)
Antibiotics	116 (33.1)	56.0	22.4	21.6
Antituberculosis	37 (10.6)	35.1	43.2	21.6
Herbal/Supplements	30 (8.6)	36.7	46.7	16.7
Antiepileptic	31 (8.9)	22.6	64.5	12.9
Cardiovascular	29 (8.3)	20.7	62.1	17.2
Statins	26 (7.4)	23.1	50.0	26.9
Antineoplastic	23 (6.6)	39.1	52.2	8.7

NSAIDs	22 (6.3)	22.7	40.9	36.4
Antifungal	22 (6.3)	40.9	50.0	9.1
Other	14 (4.0)	35.7	35.7	28.6

Antituberculosis agents ranked second at 10.6% of cases (n = 37), reflecting the significant hepatotoxicity burden associated with first-line anti-tuberculous therapy. Isoniazid, rifampicin, and pyrazinamide all carry substantial risk of hepatocellular injury, with the combination therapy posing additive or synergistic hepatotoxic effects. The relatively high frequency of herbal and dietary supplement-associated DILI (8.6%) reflects the growing use of these products and their underappreciated hepatotoxic potential. Notably, traditional herbal medicines including Polygonum multiflorum (He Shou Wu) and green tea extract have emerged as significant causes of liver injury in recent epidemiological studies.



Figure 1: Distribution of DILI injury patterns across drug categories. The horizontal stacked bar chart demonstrates the proportion of hepatocellular, cholestatic, and mixed patterns for each drug class.

Hepatocellular injury predominates across most categories, particularly with antibiotics. Cardiovascular drugs and antiepileptic agents show higher proportions of cholestatic injury

The distribution of DILI patterns varied significantly across drug categories (Figure 1). Overall, hepatocellular injury was the predominant pattern, accounting for 52.3% of all cases (n = 183), followed by cholestatic injury at 27.4% (n = 96) and mixed pattern at 20.3% (n = 71). Antibiotics demonstrated the highest proportion of hepatocellular injury (56.0%), consistent with known mechanisms involving reactive metabolite formation and mitochondrial toxicity. In contrast, cardiovascular drugs (62.1% cholestatic) and antiepileptic agents (64.5% cholestatic) showed predominantly cholestatic patterns, likely reflecting drug-specific effects on bile acid transport and metabolism.

4.3 RUCAM-Based Causality Assessment

RUCAM scoring demonstrated probable to highly probable causality in the majority of cases. The distribution of RUCAM scores across the cohort showed a peak between 6 and 8, consistent with probable causality classification (Figure 2). The mean score of 6.4 +/- 1.8 reflects the careful case selection emphasizing reasonably documented temporal relationships between drug exposure and liver injury.

Figure 4. RUCAM-Based Causality Assessment



Figure 2: RUCAM score distribution (left panel) and corresponding causality categories (right panel). The histogram demonstrates a near-normal distribution of scores centered around the probable causality range. The pie chart illustrates that 62.6% of cases were classified as probable, 23.0% as possible, and 14.4% as highly probable drug causality.

Causality assessment outcomes are presented in Table 3. Highly probable cases (RUCAM ≥ 9) were more commonly associated with drugs having well-established hepatotoxicity profiles, positive rechallenge data, or clear temporal relationships with dechallenge. Possible cases (RUCAM 3-5) typically involved complex polypharmacy scenarios where attribution to a single agent was challenging, or cases with incomplete exclusion of alternative etiologies.

RUCAM Causality Assessment Distribution

Causality Category	RUCAM Score	n (%)
Possible	3-5	80 (22.9)
Probable	6-8	219 (62.6)
Highly Probable	≥ 9	51 (14.6)

It is important to acknowledge the inherent limitations of the RUCAM instrument. Published evaluations have demonstrated moderate inter-rater reliability, with reported test-retest coefficients of approximately 0.51 and inter-rater reliability of 0.34. These limitations underscore the subjective nature of DILI causality assessment and the need for expert adjudication in research settings. In clinical practice, the RUCAM score serves as a useful guide rather than a definitive diagnostic test.

4.4 Laboratory Parameters and Clinical Outcomes

Clinical outcomes across the cohort revealed significant morbidity and mortality (Table 4). Complete recovery was achieved in 64.6% of patients (n = 226), while chronic DILI developed in 18.9% (n = 66). Severe outcomes including acute liver failure requiring transplantation and death occurred in 5.4% (n = 19) and 11.1% (n = 39) of cases, respectively. The overall mortality rate of 11.1% is consistent with published reports from international DILI registries, which document mortality rates ranging from 5% to 15% depending on case ascertainment methods and population characteristics.

Clinical Outcomes by DILI Severity Classification

Outcome	Overall n (%)	Mild n (%)	Moderate n (%)	Severe n (%)
Recovered	226 (64.6)	72 (72.0)	121 (68.8)	33 (44.6)
Chronic DILI	66 (18.9)	19 (19.0)	32 (18.2)	15 (20.3)
Death	39 (11.1)	5 (5.0)	17 (9.7)	17 (23.0)
ALF/Transplant	19 (5.4)	4 (4.0)	6 (3.4)	9 (12.2)

The severity classification demonstrated a strong association with clinical outcomes (chi-square = 26.93, degrees of freedom = 6, $p < 0.001$). Severe DILI cases (meeting Hy's law criteria) showed dramatically worse outcomes, with only 44.6% achieving complete recovery compared to 72.0% of mild cases and 68.8% of moderate cases. The combined rate of death or ALF/transplantation was 35.2% in severe cases versus 9.0% in mild and 13.1% in moderate cases, underscoring the prognostic significance of Hy's law criteria.

Figure 3. Laboratory Parameters by Clinical Outcome



Figure 3: Laboratory parameters across clinical outcome groups. Box plots illustrate ALT (left), total bilirubin (center), and INR (right) distributions for patients achieving recovery, developing chronic DILI, requiring transplantation for acute liver failure (ALF), or dying. Increasing severity of liver dysfunction markers correlates progressively with worse clinical outcomes.

Analysis of laboratory parameters across outcome groups revealed substantial differences (Figure 3). Patients who died or progressed to acute liver failure demonstrated significantly higher total bilirubin levels compared to those who recovered (median 23.3 vs. 12.6 mg/dL, $p < 0.001$ in DILIN studies). INR values were also markedly elevated in poor outcome groups, reflecting the severity of coagulopathy associated with advanced hepatic synthetic dysfunction. ALT levels showed considerable variability across all outcome groups, consistent with the observation that peak ALT values are less predictive of prognosis than markers of hepatic function such as bilirubin and INR.



Figure 4: Clinical outcomes stratified by DILI severity classification. The stacked bar chart demonstrates progressively worse outcomes with increasing severity, with severe DILI (Hy's law positive) showing the highest rates of death (23%) and acute liver failure requiring transplantation (12%).

The correlation matrix of clinical parameters (Figure 5) revealed modest intercorrelations among laboratory markers. Total bilirubin showed a weak negative correlation with ALT (r = -0.18), reflecting the different temporal patterns of these markers during DILI evolution. Age demonstrated weak positive correlations with INR (r = 0.11) but minimal correlation with liver enzyme elevations, suggesting that age-related risk may operate through mechanisms other than direct hepatotoxicity intensity.

Figure 5. Correlation Matrix of Clinical Parameters



Figure 5: Pearson correlation matrix of clinical parameters including age, ALT, total bilirubin, INR, RUCAM score, and length of stay. Color intensity indicates the strength and direction of correlations. The strongest observed correlation is the weak negative relationship between ALT and total bilirubin (r = -0.18).

4.5 Predictors of Severe DILI

Multivariate logistic regression analysis was performed to identify independent predictors of severe clinical outcomes, defined as acute liver failure requiring transplantation or death (Table 5). Among the variables analyzed, hepatocellular pattern of injury emerged as the only statistically significant independent predictor (OR 2.38, 95% CI: 1.01-5.59, p = 0.047). Patients with hepatocellular DILI had approximately 2.4-fold higher odds of experiencing severe outcomes compared to those with mixed or cholestatic patterns after adjusting for age, gender, and laboratory parameters.

Multivariate Logistic Regression for Predictors of Severe DILI Outcomes

Predictor	Adjusted OR	95% CI	p-value
Age (per year)	1.01	0.99-1.03	0.175
Male Gender	1.08	0.60-1.96	0.792
Hepatocellular Pattern	2.38	1.01-5.59	0.047
Cholestatic Pattern	0.83	0.29-2.34	0.720
ALT (per 100 U/L increase)	1.05	0.93-1.19	0.430
Total Bilirubin (per mg/dL)	1.04	0.96-1.13	0.321
INR (per unit increase)	1.12	0.81-1.55	0.511

ROC curve analysis evaluated the discriminative performance of individual laboratory markers for predicting severe outcomes (Figure 6). ALT demonstrated the highest AUC at 0.629, indicating poor to fair discriminative ability. Total bilirubin (AUC = 0.512) and INR (AUC = 0.524) showed performance near that of random chance, suggesting that in this cohort, no single laboratory parameter provided reliable prediction of severe outcomes. The limited predictive value of individual biomarkers highlights the complexity of DILI pathophysiology and the need for composite scoring systems or novel biomarkers.

The absence of strong independent predictors in this analysis reflects the inherent complexity and multifactorial nature of DILI severity. Factors not captured in this model, including genetic susceptibility markers, immune responses, drug metabolism capacity, and comorbid conditions, likely contribute substantially to outcome determination. The model's pseudo R-squared of 0.039 indicates that the included variables explain only a small proportion of outcome variance, underscoring the need for expanded prediction models incorporating novel biomarkers and genetic data.

5. DISCUSSION

5.1 Interpretation of Findings

This comprehensive analysis of 350 DILI cases provides several important insights into the contemporary epidemiology, clinical characteristics, and outcomes of drug-induced liver injury. The findings align with and extend previous observations from the DILIN, Spanish DILI registry, and prospective European cohorts, while highlighting persistent challenges in DILI prediction and management.

The female predominance observed in this cohort (61.7%) is consistent with published literature and supports the hypothesis that sex-based differences in drug metabolism, immune function, and pharmacokinetics contribute to DILI susceptibility. Estrogen-mediated effects on cytochrome P450 enzyme expression and sex-based differences in hepatic transporter activity may partially explain this observation. However, multivariate analysis did not identify female gender as an independent predictor of severe outcomes, suggesting that while women may be at higher risk of developing DILI, sex does not necessarily confer worse prognosis once injury has occurred.

The predominance of antibiotics as causative agents (33.1%) aligns closely with DILIN data reporting antimicrobial agents as the leading drug class implicated in DILI. Amoxicillin-clavulanate deserves particular mention as one of the most common individual drugs causing DILI in Western countries. The association between this widely prescribed antibiotic and hepatotoxicity is well-established, with characteristic latency periods of 1-4 weeks and a mixed or cholestatic pattern predominating. The high frequency of antibiotic-associated DILI underscores the need for enhanced awareness among prescribing physicians and consideration of alternative agents in patients with risk factors.

The significant proportion of cases attributed to herbal and dietary supplements (8.6%) reflects a concerning trend documented in recent epidemiological studies. The DILIN has reported a progressive increase in HDS-associated DILI, from approximately 7% of cases in the early 2000s to over 20% in recent cohorts. This increase likely reflects growing consumer use of these products, often without medical supervision, coupled with underappreciation of their hepatotoxic potential. Regulatory frameworks for dietary supplements vary substantially across jurisdictions, with many products containing undeclared ingredients or variable concentrations of active compounds that may contribute to hepatotoxicity.

The finding that hepatocellular pattern was an independent predictor of severe outcomes is clinically significant and consistent with established prognostic frameworks. Hepatocellular injury, particularly when accompanied by jaundice meeting Hy's law criteria, is widely recognized as a marker of potentially life-threatening DILI. The 10% mortality threshold associated with Hy's law has led regulatory agencies to require careful evaluation of any drug meeting these criteria during clinical development. In this cohort, Hy's law-positive cases demonstrated a combined death/ALF rate of 35.2%, far exceeding the 10% threshold and confirming the prognostic significance of this classification.

5.2 Implications for Clinical Practice

The findings of this study have several important implications for clinical practice. First, the substantial mortality and morbidity associated with DILI underscore the importance of systematic medication history-taking in all patients presenting with acute liver injury. Comprehensive documentation of prescription medications, over-the-counter drugs, herbal products, and dietary supplements is essential for accurate causality assessment. Physicians should maintain a high index of suspicion for DILI, particularly in patients with compatible temporal relationships between drug exposure and liver injury.

Second, the application of standardized causality assessment tools such as RUCAM can improve diagnostic accuracy and facilitate communication among healthcare providers. While RUCAM has recognized limitations, its systematic approach to evaluating temporal relationships, risk factors, alternative explanations, and published evidence provides a structured framework for clinical decision-making. In complex cases involving polypharmacy, expert hepatology consultation may be valuable for adjudicating causality.

Third, the identification of Hy's law as a critical prognostic indicator highlights the importance of careful monitoring in patients with hepatocellular DILI and elevated bilirubin. Such patients require close observation for signs of hepatic synthetic dysfunction (prolonged INR, hypoalbuminemia), encephalopathy, and renal impairment. Early transfer to centers with liver transplant capability should be considered, as transplantation represents the only life-saving intervention for patients progressing to fulminant hepatic failure.

Fourth, the emergence of herbal and dietary supplements as significant causes of DILI calls for enhanced patient education regarding the potential risks of these products. Healthcare providers should specifically inquire about supplement use, as patients may not voluntarily disclose these products. Regulatory agencies should consider strengthened oversight of the dietary supplement industry, including requirements for hepatotoxicity screening and adverse event reporting.

5.3 Impact on Drug Development

The persistent challenge of DILI in drug development demands continued innovation in preclinical and clinical safety assessment. Traditional preclinical hepatotoxicity screening, relying primarily on in vivo animal studies and in vitro cytotoxicity assays, fails to reliably predict idiosyncratic human DILI. This predictive gap stems from fundamental species differences in drug metabolism, immune responses, and genetic polymorphisms affecting drug disposition.

Several promising approaches are being developed to improve DILI prediction. Human hepatocyte-based models, including spheroid cultures and microphysiological systems, offer more physiologically relevant platforms for hepatotoxicity assessment. Integration of pharmacogenomic data, including HLA genotyping and drug metabolism enzyme polymorphism screening, may enable identification of at-risk populations. Novel biomarkers including microRNA-122, glutamate dehydrogenase, keratin-18, and high-mobility group box protein 1 show promise for improving DILI detection and prediction.

The FDA's 2016 Letter of Support for emerging DILI biomarkers represents an important regulatory milestone, encouraging the development and validation of biomarkers that could enhance liver safety assessment in clinical trials. The qualified biomarkers total keratin-18, high-mobility group box protein 1 (HMGB1), and osteopontin may provide mechanistic information about hepatocyte death pathways and enable risk stratification of patients with emerging liver injury.

Regulatory guidance continues to evolve in response to the DILI challenge. The FDA's 2009 guidance on preclinical evaluation of drug-induced liver injury and the 2023 ICH S1B(R1) addendum on carcinogenicity testing both address hepatotoxicity assessment. The European Society for Regulatory Toxicology's ongoing work on New Approach Methodologies (NAMs) aims to reduce reliance on animal testing while improving human-relevant hepatotoxicity prediction. Despite these advances, predicting idiosyncratic DILI remains one of the most significant unmet needs in drug safety science.

5.4 Limitations

Several limitations of this study should be acknowledged. First, the retrospective design introduces inherent biases including incomplete documentation, variable diagnostic workups, and selection bias toward more severe cases requiring hospitalization. Prospective cohort designs provide more standardized data collection but are resource-intensive and may not capture the full spectrum of DILI severity.

Second, the diagnosis of DILI remains fundamentally challenging due to the absence of pathognomonic biomarkers. The exclusion of alternative etiologies relies on clinical judgment and available testing, and incomplete exclusion of competing diagnoses may lead to misclassification. The RUCAM instrument, while standardized, has documented limitations in inter-rater reliability that may affect causality classification consistency.

Third, this analysis did not incorporate genetic data, limiting the ability to evaluate pharmacogenomic risk factors that have been increasingly recognized as important determinants of DILI susceptibility. Future studies incorporating HLA genotyping, drug metabolism enzyme polymorphism analysis, and transcriptomic profiling will provide more comprehensive risk stratification.

Fourth, the single-center or limited multi-center nature of data collection may limit generalizability to diverse populations with different genetic backgrounds, medication practices, and healthcare systems. Geographic and ethnic variations in DILI epidemiology are well-documented, with traditional herbal medicine use, tuberculosis prevalence, and prescribing practices influencing the distribution of causative agents.

Fifth, the relatively modest predictive performance of multivariate models highlights the incomplete understanding of factors determining DILI severity. Unmeasured variables including genetic susceptibility, immune status, drug-drug interactions, and environmental factors likely contribute substantially to outcome determination.

6. CONCLUSION

Drug-induced liver injury remains a critical challenge at the intersection of clinical medicine, pharmaceutical development, and public health. This comprehensive analysis of 350 DILI cases demonstrates the substantial burden of hepatotoxicity across diverse drug classes, with antibiotics, antituberculosis agents, and herbal supplements emerging as leading causative categories. Hepatocellular injury predominated overall and was identified as an independent predictor of severe outcomes, reinforcing the prognostic significance of clinical injury patterns.

The observation that Hy's law-positive cases experienced a combined mortality/transplantation rate of 35.2% underscores the life-threatening potential of severe DILI and the need for vigilant monitoring, early recognition, and timely intervention. The substantial proportion of

cases developing chronic DILI (18.9%) further highlights the long-term consequences of acute hepatotoxicity that extend beyond the initial injury episode.

From a drug development perspective, DILI continues to represent the leading cause of drug attrition, regulatory denial, and post-marketing withdrawal. The inability of current preclinical models to reliably predict idiosyncratic human hepatotoxicity demands continued investment in human-relevant testing platforms, pharmacogenomic integration, and novel biomarker development. The qualified emergence of microRNA-122, keratin-18 fragments, and other mechanistic biomarkers offers hope for improved liver safety assessment, though significant validation work remains.

Several priorities emerge for advancing DILI science and clinical care. Enhanced pharmacovigilance systems leveraging real-world data and artificial intelligence may improve signal detection for emerging hepatotoxicity. Integration of pharmacogenomic testing into clinical practice, particularly for drugs with well-characterized HLA associations, could enable personalized risk stratification. Development of targeted therapies for DILI, including hepatoprotective agents and immunomodulatory strategies, represents an important unmet need. Finally, clinician and patient education regarding the hepatotoxic potential of prescription drugs, over-the-counter medications, and herbal supplements is essential for prevention and early detection.

In conclusion, DILI exemplifies the complex challenges of ensuring medication safety in an era of polypharmacy, widespread supplement use, and personalized medicine. The findings of this study contribute to the growing body of evidence supporting systematic approaches to DILI diagnosis, risk stratification, and management, while highlighting the urgent need for continued research into predictive biomarkers, human-relevant preclinical models, and effective therapeutic interventions.

7. REFERENCES

1. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. *Gastroenterology*, 2015; 148(7): 1340-1352. doi:10.1053/j.gastro.2015.03.006
2. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology*, 2013; 144(7): 1419-1425. doi:10.1053/j.gastro.2013.02.006
3. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. *Hepatology*, 2010; 52(6): 2065-2076. doi:10.1002/hep.23937
4. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology*, 2014; 147(1): 96-108. doi:10.1053/j.gastro.2014.03.045
5. Andrade RJ, Aithal GP, Bjornsson ES, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol*, 2019; 70(6): 1222-1261. doi:10.1016/j.jhep.2019.02.014
6. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. *J Clin Epidemiol*, 1993; 46(11): 1323-1330. doi:10.1016/0895-4356(93)90101-6
7. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. *Clin Pharmacol Ther*., 2011; 89(6): 806-815. doi:10.1038/clpt.2011.58
8. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. *Hepatology*, 2013; 58(1): 388-396. doi:10.1002/hep.26408
9. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet*, 2009; 41(7): 816-819. doi:10.1038/ng.379
10. Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. *Gastroenterology*, 2017; 152(5): 1078-1089. doi:10.1053/j.gastro.2016.12.016
11. Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. *J Hepatol*, 2021; 75(1): 86-97. doi:10.1016/j.jhep.2021.01.028
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol*, 2019; 70(6): 1222-1261. doi:10.1016/j.jhep.2019.02.014
13. Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology*, 2014; 147(1): 109-118. doi:10.1053/j.gastro.2014.03.050
14. Li Y, Li J, Chen S, et al. Identification of high-risk drugs and demographic patterns in drug-induced liver injury: A systematic review and meta-analysis. *Sci Rep*., 2025; 15: 24262. doi:10.1038/s41598-025-24262-7
15. Fontana RJ, Seeff JR, Ostrov D, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. *Hepatology*, 2010; 52(2): 730-742. doi:10.1002/hep.23696
16. Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. *Semin Liver Dis*., 2014; 34(2): 115-122. doi:10.1055/s-0034-1375951
17. Hayashi PH, Rockey DC, Fontana RJ, et al. Death

and acute liver failure from DILI: Analysis of patients enrolled in the DILIN. *Hepatology*, 2017; 65(4): 1360-1367. doi:10.1002/hep.28917

18. Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. *Hepatology*, 2019; 69(2): 760-773. doi:10.1002/hep.29802
19. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): Application of this data organization approach to Phase III clinical trial data of the anti-VEGF receptor tyrosine kinase inhibitor vandetanib. *Hepatology*, 2011; 53(2): 602-611. doi:10.1002/hep.24061
20. US Food and Drug Administration. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. FDA, 2009. Available at: https://www.fda.gov/media/116737/download
21. Cirulli ET, Nicoletti P, Abramson K, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. *Gastroenterology*, 2019; 156(6): 1707-1716. doi:10.1053/j.gastro.2019.01.035
22. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, 2011; 141(1): 338-347. doi:10.1053/j.gastro.2011.04.001
23. Robles-Diaz M, Lucena MI, Stephens C, et al. Hepatotoxicity of herbal and dietary supplements: A 10-year prospective study in the Spanish DILI Registry. *J Hepatol*, 2018; 68(5): S102. doi:10.1016/S0618-8278(18)30389-1.
24. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. *Semin Liver Dis*., 2014; 34(2): 172-193. doi:10.1055/s-0034-1375950
25. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. *Hepatol Int*., 2017; 11(3): 221-241. doi:10.1007/s12072-017-9811-2